CA2981861A1 - Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use - Google Patents

Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use Download PDF

Info

Publication number
CA2981861A1
CA2981861A1 CA2981861A CA2981861A CA2981861A1 CA 2981861 A1 CA2981861 A1 CA 2981861A1 CA 2981861 A CA2981861 A CA 2981861A CA 2981861 A CA2981861 A CA 2981861A CA 2981861 A1 CA2981861 A1 CA 2981861A1
Authority
CA
Canada
Prior art keywords
esters
formulations
apocarotenoid
preparation
glycosaminoglycan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2981861A
Other languages
English (en)
French (fr)
Inventor
Nikla BARICORDI
Roberto Merighi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyalblue Srl
Original Assignee
Hyalblue Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyalblue Srl filed Critical Hyalblue Srl
Publication of CA2981861A1 publication Critical patent/CA2981861A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA2981861A 2015-04-07 2016-04-07 Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use Abandoned CA2981861A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI2015A000102 2015-04-07
ITFI20150102 2015-04-07
PCT/IB2016/051960 WO2016162809A1 (en) 2015-04-07 2016-04-07 Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use

Publications (1)

Publication Number Publication Date
CA2981861A1 true CA2981861A1 (en) 2016-10-13

Family

ID=53719816

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2981861A Abandoned CA2981861A1 (en) 2015-04-07 2016-04-07 Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use

Country Status (12)

Country Link
US (1) US10328097B2 (cg-RX-API-DMAC10.html)
EP (1) EP3280396B1 (cg-RX-API-DMAC10.html)
JP (1) JP6847091B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180002674A (cg-RX-API-DMAC10.html)
CN (1) CN107636020A (cg-RX-API-DMAC10.html)
AU (1) AU2016244391B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017021608A2 (cg-RX-API-DMAC10.html)
CA (1) CA2981861A1 (cg-RX-API-DMAC10.html)
ES (1) ES2888648T3 (cg-RX-API-DMAC10.html)
MA (1) MA41912A (cg-RX-API-DMAC10.html)
RU (1) RU2726192C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016162809A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000012535A1 (it) * 2020-05-27 2021-11-27 Stefano Colombo Composizione oftalmica a base di acido ialuronico per la protezione dai danni causati dall’inquinamento ambientale
WO2022094695A1 (en) 2020-11-03 2022-05-12 Institut National De La Recherche Scientifique A method and a system for compressed ultrafast tomographic imaging
CN116284495B (zh) * 2023-03-20 2024-08-30 润辉生物技术(威海)有限公司 全反式维甲酸低分子透明质酸酯衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1281877B1 (it) * 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici
ITTS20010017A1 (it) * 2001-07-17 2003-01-17 Ct Ricerche Polytech Soc Coop Esteri polisaccaridici di acido retinoico.
ITMI20022745A1 (it) * 2002-12-23 2004-06-24 Coimex Scrl United Companies Esteri misti dell'acido ialuronico ad attivita' citostatica e prodifferenziante e procedimento per la loro produzione.
ITMI20030043A1 (it) * 2003-01-14 2004-07-15 Coimex S C R L United Companies Uso di esteri retinoici dell'acido ialuronico in cellule
WO2005077176A1 (en) * 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
ITMI20040347A1 (it) * 2004-02-26 2004-05-26 Pharma Medical Ltd Nuovo farmaco di associazione
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
ITMI20062134A1 (it) * 2006-11-08 2008-05-09 Cbb Net S A Preparaziobne di esteri della diacereina con acido ialuronico e loro formulazioni per l'impiego farmaceutico
US8865685B2 (en) * 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
CA2886115A1 (en) * 2012-10-02 2014-04-10 Allergan, Inc. Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes

Also Published As

Publication number Publication date
EP3280396A1 (en) 2018-02-14
AU2016244391A1 (en) 2017-11-23
JP2018510962A (ja) 2018-04-19
ES2888648T3 (es) 2022-01-05
AU2016244391B2 (en) 2020-11-19
US10328097B2 (en) 2019-06-25
CN107636020A (zh) 2018-01-26
RU2017138283A (ru) 2019-05-07
MA41912A (fr) 2018-02-13
WO2016162809A1 (en) 2016-10-13
JP6847091B2 (ja) 2021-03-24
BR112017021608A2 (pt) 2018-07-03
RU2017138283A3 (cg-RX-API-DMAC10.html) 2019-09-30
EP3280396B1 (en) 2021-06-23
RU2726192C2 (ru) 2020-07-09
US20180117077A1 (en) 2018-05-03
KR20180002674A (ko) 2018-01-08

Similar Documents

Publication Publication Date Title
EP3280396B1 (en) Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use
WO2023006108A1 (zh) 一种全分子量分布的透明质酸钠及其制备方法和应用
CA2947065A1 (en) Aqueous ophthalmic solution and method for treating dry eye syndrome
CN105663160A (zh) 一种眼元素滴眼液及其制备方法
EP2542233A1 (en) Composition comprising as active ingredient l-carnitine in combination with hydroxykynurennine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
WO2016114397A1 (ja) コンドロイチン硫酸架橋体、並びにこれを含有する組成物、及び眼疾患処置剤
CN108484795A (zh) 硫酸软骨素锂及其制备方法和应用
WO2025092626A1 (zh) 一类工程细胞及应用
JP2022125363A (ja) 眼科組成物
JPH08508505A (ja) 血管形成の抑制、制御、退化のためのヒアルロン酸およびnsaidを含有する組成物
CN111202746B (zh) 一种眼用复合制剂及其制备方法
JP2015507070A (ja) 部分的に解重合したグリコサミノグリカン銀及び金塩
CN118948646B (zh) 一种含麦角硫因的眼部护理组合物及其制备方法和应用
EA017752B1 (ru) Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения отека роговицы
US20170333511A1 (en) Composition comprising hyaluronic acid and roc® and its use
CN102716117A (zh) 柚皮素在制备抗视网膜光感受器细胞凋亡的药物中的应用
JPWO2006035969A1 (ja) キサンタンガムおよびアミノ酸を含有する眼科用組成物
EP3496761B1 (en) Functionalized hyaluronic acid
US20230149440A1 (en) Ophthalmic liquid composition comprising low molecular weight linear hyaluronic acid
CN117530921A (zh) 透明质酸-瑞巴派特偶联物及其制备方法和眼用滴眼液
CN117586432A (zh) 一种透明质酸锌的制备方法及其应用
CN121129885A (zh) 一种适用于青少年缓解近视的眼部护理液及其制备方法
Zhao et al. The Latest Research Progress on Ocular Damage Caused by LED Blue Light

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210309

FZDE Discontinued

Effective date: 20230906